Oryl Photonics, an EPFL spinoff founded by Orly Tarun and Nathan Dupertuis, has developed a laboratory instrument using advanced nonlinear light scattering to measure how drug molecules dissolve. Its product uses a novel ‘Solvent Redistribution’ method and automates solubility testing while requiring minimal compound quantities. The technology targets pharmaceutical and biotechnological R&D by providing rapid, sensitive and accurate solubility measurements with lower chemical, electricity and consumable use. Oryl’s instrument aims to simplify analysis and reduce environmental impact compared with existing technologies. The company is participating in a consortium project to accelerate commercialization and broaden applications in drug discovery and development. The articles do not report other operating metrics or prior financings. Oryl Photonics builds highly efficient solubility-measurement technology aimed at pharmaceutical and life science companies. The Vaud-based startup has been supported by Western Switzerland’s life sciences innovation ecosystem, including FIT, GENILEM, École polytechnique fédérale de Lausanne and Innosuisse. The company was founded/led by Orly Tarun and Nathan Dupertuis (names given in the post). Oryl Photonics announced a CHF 830,000 seed funding round. The LinkedIn post expresses anticipation about bringing the technology to market. No operating metrics or prior financing rounds are disclosed in the article.

Total raised

$4M

Funding rounds

2

Latest round

Grant

Latest activity

Aug 2024